Gastroenterologist speaks out over biosimilar switching

Switching between infliximab and its biosimilar Inflectra must be minimised until there is more evidence that the practice is safe, a senior gastroenterologist has argued.

Dr Gregory Moore, who chairs the Australian Inflammatory Bowel Disease Association, says the decision to allow Inflectra and infliximab to be interchangeable at the point of pharmacist dispensing has “caused concerns for clinicians and patients”.